The data published in the "International Journal of Neuroscience" also found that the treatment is safe.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) and its Danish partner H. Lundbeck A/S (KFS: LUN) today reported that newly published long-term data confirm that their Azilect drug for Parkinson’s disease is effective and safe. The results are from the TEMPO study and its open-label extension.
The data was published in the June 2010 issue of the "International Journal of Neuroscience".
"The high proportion of patients (46%) remaining on Azilect monotherapy after two years in the trial suggests that starting Azilect earlier in the treatment paradigm offers us an effective and safe alternative to using dopamine agonists for an extended period of time Dr. Mark Lew, lead investigator and vice chairmain of the Department of Neurology and Director of the Division of Movement Disorders, Keck School of Medicine of the University of Southern California. “These results provide added support for a growing approach to treating patients with Parkinson’s disease earlier in the course of their disease as was also shown in the ADAGIO study."
Teva's share price rose 0.8% at the opening on Nasdaq today to $49.98, but fell 1.8% on the TASE to NIS 186.
Published by Globes [online], Israel business news - www.globes-online.com - on August 5, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010